Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma
Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage t...
Gespeichert in:
| Veröffentlicht in: | Pediatric blood & cancer 2022-04, Vol.69 (4), p.e29557-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 4 |
| container_start_page | e29557 |
| container_title | Pediatric blood & cancer |
| container_volume | 69 |
| creator | Vinti, Luciana Pagliara, Daria Buffardi, Salvatore Di Ruscio, Valentina Stocchi, Francesca Mariggiò, Elena Parasole, Rosanna Di Matteo, Antonia Petruzziello, Fara Paganelli, Valeria De Vito, Rita Del Bufalo, Francesca Strocchio, Luisa Locatelli, Franco |
| description | Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90–120 mg/m2 on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3‐year overall and progression‐free survivals are 78.1% and 67%, respectively. |
| doi_str_mv | 10.1002/pbc.29557 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2624953619</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2624953619</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3887-97364841ed369bea2cb3c4f4874e5816207e5b0097725b1ab0e9bbc6816d33683</originalsourceid><addsrcrecordid>eNp1kctO3DAUhq2qqFBg0ReoLHVDFwN2HNvJsjPiUgkJFu068uUMmCZxaidAnoDX7hkGWCBVsmRb5_Mnn_MT8oWzY85YcTJYd1zUUuoPZI_LUi4k4_rj25nVu-RzzneIKiarT2RXSM50pdUeeVom6MfpMXTG0nvwcQw9xeViZ0NvxhB7-hDGW2qh96abMtZhAwzggxlTcHRACh2ZxkTnOPU31PipxfvzuwStGTL4TTXBOhk3xjTTi-hv_qCmnbvhNnbmgOysTZvh8GXfJ7_PTn-tLhaXV-c_Vz8uF05UlV7UWqiyKjl4oWoLpnBWuHJdVroEWXFVMA3SYsdaF9JyYxnU1jqFJS-EqsQ-Odp6hxT_TpDHpgvZQduaHuKUm0IVZS2F4jWi396hd3FKPf4OKcE0TldzpL5vKZdizthhMyQcZpobzppNOg2m0zyng-zXF-NkO_Bv5GscCJxsgYfQwvx_U3O9XG2V_wBVN5rG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2630715471</pqid></control><display><type>article</type><title>Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Vinti, Luciana ; Pagliara, Daria ; Buffardi, Salvatore ; Di Ruscio, Valentina ; Stocchi, Francesca ; Mariggiò, Elena ; Parasole, Rosanna ; Di Matteo, Antonia ; Petruzziello, Fara ; Paganelli, Valeria ; De Vito, Rita ; Del Bufalo, Francesca ; Strocchio, Luisa ; Locatelli, Franco</creator><creatorcontrib>Vinti, Luciana ; Pagliara, Daria ; Buffardi, Salvatore ; Di Ruscio, Valentina ; Stocchi, Francesca ; Mariggiò, Elena ; Parasole, Rosanna ; Di Matteo, Antonia ; Petruzziello, Fara ; Paganelli, Valeria ; De Vito, Rita ; Del Bufalo, Francesca ; Strocchio, Luisa ; Locatelli, Franco</creatorcontrib><description>Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90–120 mg/m2 on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3‐year overall and progression‐free survivals are 78.1% and 67%, respectively.</description><identifier>ISSN: 1545-5009</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.29557</identifier><identifier>PMID: 35107876</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bendamustine Hydrochloride - adverse effects ; Brentuximab Vedotin ; Child ; Hematology ; Hodgkin Disease - pathology ; Hodgkin lymphoma ; Hodgkin's lymphoma ; Humans ; Immunoconjugates - therapeutic use ; Immunotherapy ; Lymphoma ; Monoclonal antibodies ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - etiology ; Oncology ; Patients ; pediatric ; Pediatrics ; refractory ; relapse ; Retrospective Studies ; Targeted cancer therapy ; Treatment Outcome ; Young Adult ; Young adults</subject><ispartof>Pediatric blood & cancer, 2022-04, Vol.69 (4), p.e29557-n/a</ispartof><rights>2022 Wiley Periodicals LLC</rights><rights>2022 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3887-97364841ed369bea2cb3c4f4874e5816207e5b0097725b1ab0e9bbc6816d33683</citedby><cites>FETCH-LOGICAL-c3887-97364841ed369bea2cb3c4f4874e5816207e5b0097725b1ab0e9bbc6816d33683</cites><orcidid>0000-0003-2803-992X ; 0000-0002-7976-3654</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpbc.29557$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpbc.29557$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35107876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vinti, Luciana</creatorcontrib><creatorcontrib>Pagliara, Daria</creatorcontrib><creatorcontrib>Buffardi, Salvatore</creatorcontrib><creatorcontrib>Di Ruscio, Valentina</creatorcontrib><creatorcontrib>Stocchi, Francesca</creatorcontrib><creatorcontrib>Mariggiò, Elena</creatorcontrib><creatorcontrib>Parasole, Rosanna</creatorcontrib><creatorcontrib>Di Matteo, Antonia</creatorcontrib><creatorcontrib>Petruzziello, Fara</creatorcontrib><creatorcontrib>Paganelli, Valeria</creatorcontrib><creatorcontrib>De Vito, Rita</creatorcontrib><creatorcontrib>Del Bufalo, Francesca</creatorcontrib><creatorcontrib>Strocchio, Luisa</creatorcontrib><creatorcontrib>Locatelli, Franco</creatorcontrib><title>Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma</title><title>Pediatric blood & cancer</title><addtitle>Pediatr Blood Cancer</addtitle><description>Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90–120 mg/m2 on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3‐year overall and progression‐free survivals are 78.1% and 67%, respectively.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bendamustine Hydrochloride - adverse effects</subject><subject>Brentuximab Vedotin</subject><subject>Child</subject><subject>Hematology</subject><subject>Hodgkin Disease - pathology</subject><subject>Hodgkin lymphoma</subject><subject>Hodgkin's lymphoma</subject><subject>Humans</subject><subject>Immunoconjugates - therapeutic use</subject><subject>Immunotherapy</subject><subject>Lymphoma</subject><subject>Monoclonal antibodies</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - etiology</subject><subject>Oncology</subject><subject>Patients</subject><subject>pediatric</subject><subject>Pediatrics</subject><subject>refractory</subject><subject>relapse</subject><subject>Retrospective Studies</subject><subject>Targeted cancer therapy</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><subject>Young adults</subject><issn>1545-5009</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctO3DAUhq2qqFBg0ReoLHVDFwN2HNvJsjPiUgkJFu068uUMmCZxaidAnoDX7hkGWCBVsmRb5_Mnn_MT8oWzY85YcTJYd1zUUuoPZI_LUi4k4_rj25nVu-RzzneIKiarT2RXSM50pdUeeVom6MfpMXTG0nvwcQw9xeViZ0NvxhB7-hDGW2qh96abMtZhAwzggxlTcHRACh2ZxkTnOPU31PipxfvzuwStGTL4TTXBOhk3xjTTi-hv_qCmnbvhNnbmgOysTZvh8GXfJ7_PTn-tLhaXV-c_Vz8uF05UlV7UWqiyKjl4oWoLpnBWuHJdVroEWXFVMA3SYsdaF9JyYxnU1jqFJS-EqsQ-Odp6hxT_TpDHpgvZQduaHuKUm0IVZS2F4jWi396hd3FKPf4OKcE0TldzpL5vKZdizthhMyQcZpobzppNOg2m0zyng-zXF-NkO_Bv5GscCJxsgYfQwvx_U3O9XG2V_wBVN5rG</recordid><startdate>202204</startdate><enddate>202204</enddate><creator>Vinti, Luciana</creator><creator>Pagliara, Daria</creator><creator>Buffardi, Salvatore</creator><creator>Di Ruscio, Valentina</creator><creator>Stocchi, Francesca</creator><creator>Mariggiò, Elena</creator><creator>Parasole, Rosanna</creator><creator>Di Matteo, Antonia</creator><creator>Petruzziello, Fara</creator><creator>Paganelli, Valeria</creator><creator>De Vito, Rita</creator><creator>Del Bufalo, Francesca</creator><creator>Strocchio, Luisa</creator><creator>Locatelli, Franco</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2803-992X</orcidid><orcidid>https://orcid.org/0000-0002-7976-3654</orcidid></search><sort><creationdate>202204</creationdate><title>Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma</title><author>Vinti, Luciana ; Pagliara, Daria ; Buffardi, Salvatore ; Di Ruscio, Valentina ; Stocchi, Francesca ; Mariggiò, Elena ; Parasole, Rosanna ; Di Matteo, Antonia ; Petruzziello, Fara ; Paganelli, Valeria ; De Vito, Rita ; Del Bufalo, Francesca ; Strocchio, Luisa ; Locatelli, Franco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3887-97364841ed369bea2cb3c4f4874e5816207e5b0097725b1ab0e9bbc6816d33683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bendamustine Hydrochloride - adverse effects</topic><topic>Brentuximab Vedotin</topic><topic>Child</topic><topic>Hematology</topic><topic>Hodgkin Disease - pathology</topic><topic>Hodgkin lymphoma</topic><topic>Hodgkin's lymphoma</topic><topic>Humans</topic><topic>Immunoconjugates - therapeutic use</topic><topic>Immunotherapy</topic><topic>Lymphoma</topic><topic>Monoclonal antibodies</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - etiology</topic><topic>Oncology</topic><topic>Patients</topic><topic>pediatric</topic><topic>Pediatrics</topic><topic>refractory</topic><topic>relapse</topic><topic>Retrospective Studies</topic><topic>Targeted cancer therapy</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vinti, Luciana</creatorcontrib><creatorcontrib>Pagliara, Daria</creatorcontrib><creatorcontrib>Buffardi, Salvatore</creatorcontrib><creatorcontrib>Di Ruscio, Valentina</creatorcontrib><creatorcontrib>Stocchi, Francesca</creatorcontrib><creatorcontrib>Mariggiò, Elena</creatorcontrib><creatorcontrib>Parasole, Rosanna</creatorcontrib><creatorcontrib>Di Matteo, Antonia</creatorcontrib><creatorcontrib>Petruzziello, Fara</creatorcontrib><creatorcontrib>Paganelli, Valeria</creatorcontrib><creatorcontrib>De Vito, Rita</creatorcontrib><creatorcontrib>Del Bufalo, Francesca</creatorcontrib><creatorcontrib>Strocchio, Luisa</creatorcontrib><creatorcontrib>Locatelli, Franco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric blood & cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vinti, Luciana</au><au>Pagliara, Daria</au><au>Buffardi, Salvatore</au><au>Di Ruscio, Valentina</au><au>Stocchi, Francesca</au><au>Mariggiò, Elena</au><au>Parasole, Rosanna</au><au>Di Matteo, Antonia</au><au>Petruzziello, Fara</au><au>Paganelli, Valeria</au><au>De Vito, Rita</au><au>Del Bufalo, Francesca</au><au>Strocchio, Luisa</au><au>Locatelli, Franco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma</atitle><jtitle>Pediatric blood & cancer</jtitle><addtitle>Pediatr Blood Cancer</addtitle><date>2022-04</date><risdate>2022</risdate><volume>69</volume><issue>4</issue><spage>e29557</spage><epage>n/a</epage><pages>e29557-n/a</pages><issn>1545-5009</issn><eissn>1545-5017</eissn><abstract>Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90–120 mg/m2 on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3‐year overall and progression‐free survivals are 78.1% and 67%, respectively.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>35107876</pmid><doi>10.1002/pbc.29557</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-2803-992X</orcidid><orcidid>https://orcid.org/0000-0002-7976-3654</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1545-5009 |
| ispartof | Pediatric blood & cancer, 2022-04, Vol.69 (4), p.e29557-n/a |
| issn | 1545-5009 1545-5017 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2624953619 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bendamustine Hydrochloride - adverse effects Brentuximab Vedotin Child Hematology Hodgkin Disease - pathology Hodgkin lymphoma Hodgkin's lymphoma Humans Immunoconjugates - therapeutic use Immunotherapy Lymphoma Monoclonal antibodies Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - etiology Oncology Patients pediatric Pediatrics refractory relapse Retrospective Studies Targeted cancer therapy Treatment Outcome Young Adult Young adults |
| title | Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T02%3A35%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Brentuximab%20vedotin%20in%20combination%20with%20bendamustine%20in%20pediatric%20patients%20or%20young%20adults%20with%20relapsed%20or%20refractory%20Hodgkin%20lymphoma&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=Vinti,%20Luciana&rft.date=2022-04&rft.volume=69&rft.issue=4&rft.spage=e29557&rft.epage=n/a&rft.pages=e29557-n/a&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.29557&rft_dat=%3Cproquest_cross%3E2624953619%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2630715471&rft_id=info:pmid/35107876&rfr_iscdi=true |